ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced the start of a Phase 1 first-in-human clinical trial ...
ProtoKinetix has announced the start of a phase 1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results